{
  "ticker": "RHT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975094",
  "id": "02975094",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0952",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mcd597pc3970.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Highlights:**  \n- **Operational Performance:**  \n  - **Receipts from customers:** $2.7M (quarter), ~$1.3M net operating cashflow (full year).  \n  - **Clinical Trials:**  \n    - First 10 patients dosed in **$13.8M pharma trial** (on schedule).  \n    - Completed **major clinical trial services agreement** (Aug 2023) with master file delivered.  \n  - **TrialsWest Expansion:**  \n    - Osborne Park site now **profitable**; third site (Mandurah) secured, operational next quarter.  \n  - **SaMD Contracts:** ~**$4.5M** in new/extended contracts (2\u20134-year terms) with global pharma clients.  \n  - **Technology:** \u2018Bridge Project\u2019 (PACS integration) in commercial testing to improve workflow.  \n\n#### **Financials:**  \n- **Cash at bank:** **$3.0M** (net cash **$0.1M** after $2.9M debt).  \n- **Debt:** **$2.9M** outstanding (NAB facility, BBSY + 2.5%, expiry Mar 2027).  \n\n#### **Outlook:**  \n- Strong FY26 pipeline: Active bids, expanding TrialsWest footprint, and SaMD demand.  \n\n*No material capital raising, trading halt, or valuation-sensitive updates identified.*",
  "usage": {
    "prompt_tokens": 4954,
    "completion_tokens": 315,
    "total_tokens": 5269,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T00:08:54.298658"
}